Relapse of lupus nephritis more than 10 years after complete remission

Nephrology Dialysis Transplantation

Volumn 20, Issue 9, 2005, Pages 1994-1998

  Carlavilla, Ana ^a   Gutiérrez, Eduardo ^a   Ortuño, Teresa ^a   Morales, Enrique ^a   González, Ester ^a   Praga, Manuel ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Focal lupus nephritis; Follow up of quiescent lupus patients; Lupus nephritis; Mycophenolate mofetil treatment; Renal lupus relapses

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; LOSARTAN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CHILD; CLINICAL FEATURE; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CLASSIFICATION; DRUG SUBSTITUTION; ELECTRON MICROSCOPY; FEMALE; FOLLOW UP; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NAUSEA AND VOMITING; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; RETREATMENT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 24044493948     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh954     Document Type: Article

References (10)

1. Ponticelli C, Moroni G. Flares in lupus nephritis: Incidence, impact on renal survival and management. Lupus 1998; 7: 635
2. Austin HA, Balow JE. Natural history and treatment of lupus nephritis. Semin Nephrol 1999; 19: 2-11
3. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46: 995-1002
4. El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA. Relapses of lupus nephritis: Incidence, risk factors, serology and impact on outcome. Lupus 2003; 12: 692-696
5. Mok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50: 2559-2568
6. Ponticelli C, Moroni G, Banfi G. Discontinuation of therapy in diffuse proliferative lupus nephritis. Am J Med 1988; 85: 275
7. Moroni G, Greloni GC, Ponticelli C. Late recurrence of lupus nephritis after long-term clinical remission. Nephrol Dial Transplant 2001; 16: 849-852
8. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33: 634-643
9. Ioannidis JP, Boki KA, Katsorida ME et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258-264
10. Ciruelo E, de la Cruz J, Lopez I, Gómez Reino JJ. Cumulative rate of relapse of lupus nephritis alter successful treatment with cyclophosphamide. Arthritis Rheum 1996; 39: 2028-2034